title: The association of hematologic parameters on the prognosis of patients with metastatic renal cell carcinoma.
abstract: OBJECTIVE
  Metastatic renal cell carcinoma (mRCC) bears a poor prognosis. We investigated the prognostic significance of some hematologic parameters of patients with mRCC.
  
  
  METHODS
  We retrospectively reviewed the records of 53 patients with mRCC . The mean follow up time was 34 months (range 5-142).We assessed the prognostic value of hematologic parameters (leukocytes ,neutrophils, lymphocytes, platelets, neutrophil to lymphocyte ratio/NLR, platelet to lymphocyte ratio/PLR), and other clinical parameters with univariate and multivariate analysis.
  
  
  RESULTS
  Memorial Sloan-Kettering Cancer Center (MSKCC) risk group , lung metastases, sunitinib treatment, lymphocyte count, NLR, and anemia significantly correlated with median overall survival (OS) on univariate analysis. The median OS in patients with a NLR < 3.4 was 32.2 months , significantly higher than the 13.9 months in patients with a ratio ≥ 3.4 (p = 0.006). Multivariate analysis revealed that MSKCC risk group and the NLR were independent predictors of OS.
  
  
  CONCLUSIONS
  Hematologic parameters may be associated with OS in mRCC. However, further studies are needed to establish their routine use.
authors.affiliation: Department of Medical Oncology, Izmir Katip Celebi University, Ataturk Training and Research Hospital, Ismir, Turkey.
authors.forename: A
authors.initials: A
authors.lastname: Dirican
authors.forename: Y
authors.initials: Y
authors.lastname: Kucukzeybek
authors.forename: I
authors.initials: I
authors.lastname: Somali
authors.forename: C
authors.initials: C
authors.lastname: Erten
authors.forename: L
authors.initials: L
authors.lastname: Demir
authors.forename: A
authors.initials: A
authors.lastname: Can
authors.forename: K
authors.initials: K
authors.lastname: Bahriye Payzin
authors.forename: I
authors.initials: I
authors.lastname: Vedat Bayoglu
authors.forename: M
authors.initials: M
authors.lastname: Akyol
authors.forename: M
authors.initials: M
authors.lastname: Koseoglu
authors.forename: A
authors.initials: A
authors.lastname: Alacacioglu
authors.forename: M
authors.initials: M
authors.lastname: Oktay Tarhan
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001792:Blood Platelets; D002292:Carcinoma, Renal Cell / Q000097:blood* / Q000401:mortality / Q000556:secondary* / Q000628:therapy; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D053208:Kaplan-Meier Estimate; D007680:Kidney Neoplasms / Q000097:blood* / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D018655:Lymphocyte Count; D008214:Lymphocytes; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009504:Neutrophils; D010976:Platelet Count; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D012189:Retrospective Studies; D012307:Risk Factors; D000077210:Sunitinib; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D000077210:Sunitinib